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Other names: Autotaxin; ATX; NPP2; PD1alpha; 
lysophospholipase D; PDNP2 
Location: 8q24.12 
Local order: Telomeric to NOV (nephroblastoma 
overxpressed gene), centromeric to TAF2; colocalized 
with pseudogene CYCSP23. 
DNA/RNA 
Note: mRNA length 3276 or 3120 bp, depending upon 
alternate splicing. 
Description 
The ENPP2 gene is 81,754 bp in length and is 
composed of 26 exons. Part of exon 1 and 26 are 
untranslated (UTR); translation extends from the  
remainder of exon 1 through the proximal portion of  
exon 26; however, there is a 152 bp exon (exon 12) that 
is alternatively spliced and is included primarily n 
neurally derived tissues. 
Transcription 
The mRNA for ENPP2 is 3276 bp with exon 12 and 
3120 bp without it. The ENPP2 promoter is reported to 
have four SP1 sites as well as binding sites for NFAT 
and NF-kappaB but no TATA or CAAT boxes. The 
only transcription factor that has been proven to 
increase ENPP2 protein expression is 
NFATC2/NFAT1, after release of alpha6beta4 from 
hemidesmosomes in a breast cancer cell line. A number 
of growth factors have been found to stimulate ENPP2 
protein expression, while several inflammatory 








ENPP2 Gene: Intron-exon organization of ENPP2. 
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The ENPP2 protein, NPP2 or ATX, is an N-
glycolsylated member of the ecto-nucleotide 
pyrophosphatase and phosphodiesterase (NPP) family 
of proteins. The NPP2 precursor contains 915 amino 
acids, 105.2 KDa; and an alternately spliced variant is 
863 amino acids, 99.0 KDa. The amino terminal signal 
peptide sequence is cleaved at a signal peptidase site 
between G27 and F28 to yield a secreted protein that 
contains 888/836 amino acids, 102.3/96.9 KDa. NPP2 
contains up to 3 ASN-linked glycosylation sites that 
appear to be required for secretion as well as for 
stabilization of its active conformation. 
Expression 
NPP2 is expressed in many tissues during development, 
but it is critical for blood vessel maturation and 
neurogenesis. Certain inflammatory cytokines and the 
tumor suppressor CST6 downregulate ENPP2 
expression, and some of the NPP2 products exert a 
negative feedback on its expression. Conversely, a 
number of growth factors as well as EBV infection (i  
Hodgkin's lymphoma) upregulate ENPP2 expression. 
Disruption of hemidesmosomes in breast cancer cells 
releases alpha6beta4, which initiates a signaling 
cascade that culminates in the activation of the 
transcription factor NFAT1, which binds to the ENPP2 
promoter to upregulate protein expression. 
Upregulation of ENPP2 has been reported in a number 
of aggressive tumors, including glioblastoma, 
undifferentiated anaplastic thyroid carcinoma, invasi e 
breast carcinoma, and metastatic hepatocellular 
carcinoma. 
In adults, NPP2 is the major source of serum and 
plasma lysophospholipase D activity. It is also highly 
expressed in brain, kidney, liver, ovary, small intestine, 
and placenta, and is present in many other tissues. 
Function 
NPP2 is a Type 2 nucleotide pyrophosphatase and 
phosphodiesterase that also has ATPase activity. In 
addition, NPP2 is the major source of serum and 
plasma lysophospholipase D activity, hydrolyzing 
lysophosphatidylcholine into lysophosphatidic acid as 
well as cyclic phosphatidic acid. NPP2 also hydrolyzes 
sphingosylphosphorylcholine into sphingosine-1-
phosphate; however, NPP2 is not a major source of 
sphingosine-1-phosphate in plasma. The production of 
lysophosphatidic acid is thought to account for many of 
the physiological and pathological roles of ENPP2. 
Both enzymatic activities of NPP2 share a common 
catalytic domain. Like other members of the NPP 
family, NPP2 is a metallo-enzyme with binding sites 
for 2 metal atoms coordinated by three critical 
histidines (H316, H360, and H475) and associated 
aspartates (D172, D312, and D359). T210 is 
nucleotidylated during the nucleotide 
pyrophosphatase/phosphodiesterase reaction and is 
essential for hydrolysis of substrate during the 
lysophospholipase D reaction as well. 
Homology 
NPP2 is a member of the nucleotide pyrophosphatase 
and phosphodiesterase family, which includes ENPP1 
(PC1) and ENPP3 (B10). Although the catalytic 
domain is highly conserved within this family of 
proteins, only NPP2 possesses lysophospholipase D 
activity. 
Mutations 
Note: There are a number of single nucleotide 
polymorphisms (SNPs) that have been reported within 
the ENPP2 gene but none are yet reported to be 
associated with altered phenotype. However, knockout 
of ENPP2 is lethal in mice (approximately E12), 
therefore mutations associated with loss of functio 




Overexpression of the ENPP2 protein has been 
associated with tumor cell motility and invasion, tumor 
growth and metastasis, and blood vessel formation. 
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Prognosis 
ENPP2 is over-expressed in poorly differentiated non-
small cell lung carcinomas and invasive and metastatic 
hepatocellular carcinoma. In thyroid carcinomas, 
ENPP2 expression was found to be higher in 
undifferentiated anaplastic thyroid carcinoma cell lines 
and tissues than in follicular thyroid carcinomas or 
goiters. When glioblastoma multiforme cells were 
collected from tumor cores vs. areas of white matter 
invasion, ENPP2 was found to be overexpressed 
predominantly at the invasive front. 
Oncogenesis 
Upregulation of NPP2 expression appears to be 
associated with cancer progression rather than with 
oncogenesis. Transfection of ENPP2 cDNA into mouse 
fibroblast cell lines (NIH3T3 clone7) did not result in 
tumorigenic cell lines, but transfection into Ras-
transformed fibroblasts resulted in rapidly growing, 
hematogenous, highly metastatic tumors. NPP2 
expression was found in Hodgkin's lymphoma cells as 
well as in CD30+ anaplastic large-cell lymphomas. In 
the Hodgkin's lymphomas, EBV infection was 
correlated to induction of ENPP2 expression (P = 
0.006). 
Transfection of the tumor suppressor CST6 into MDA-
MB-435 cells resulted in down-regulation of ENPP2. In 
contrast, down regulation of ENPP2 by specific 
siRNAs resulted in down-regulation of the tumor 
suppressors, thrombospondin-1 and thrombospondin-2 
(THBS1 and THBS2, respectively). 
Diabetes 
Disease 
NPP2 expression is highly upregulated during 
adipocyte differentiation and its product, 
lysophosphatidic acid, stimulates proliferation in 
preadipocytes. In genetically obese, diabetic mice, 
NPP2 expression was increased in adipose tissue 
compared to their lean siblings. This is a possible 
model for type 2 diabetes, which has a strong genetic 
component. 
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